851 related articles for article (PubMed ID: 14755775)
1. Liver transplantation for hepatocellular carcinoma: the MELD impact.
Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
[TBL] [Abstract][Full Text] [Related]
2. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
[TBL] [Abstract][Full Text] [Related]
3. Liver transplantation in the MELD era: a single-center experience.
Sachdev M; Hernandez JL; Sharma P; Douglas DD; Byrne T; Harrison ME; Mulligan D; Moss A; Reddy K; Vargas HE; Rakela J; Balan V
Dig Dis Sci; 2006 Jun; 51(6):1070-8. PubMed ID: 16865573
[TBL] [Abstract][Full Text] [Related]
4. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
Yao FY; Bass NM; Ascher NL; Roberts JP
Liver Transpl; 2004 May; 10(5):621-30. PubMed ID: 15108253
[TBL] [Abstract][Full Text] [Related]
5. Model for end-stage liver disease: did the new liver allocation policy affect waiting list mortality?
Austin MT; Poulose BK; Ray WA; Arbogast PG; Feurer ID; Pinson CW
Arch Surg; 2007 Nov; 142(11):1079-85. PubMed ID: 18025337
[TBL] [Abstract][Full Text] [Related]
6. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD.
Hayashi PH; Trotter JF; Forman L; Kugelmas M; Steinberg T; Russ P; Wachs M; Bak T; Kam I; Everson GT
Liver Transpl; 2004 Jan; 10(1):42-8. PubMed ID: 14755776
[TBL] [Abstract][Full Text] [Related]
7. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation.
Sharma P; Harper AM; Hernandez JL; Heffron T; Mulligan DC; Wiesner RH; Balan V
Am J Transplant; 2006 Aug; 6(8):1957-62. PubMed ID: 16771808
[TBL] [Abstract][Full Text] [Related]
8. The sickest first? Disparities with model for end-stage liver disease-based organ allocation: one region's experience.
Schaffer RL; Kulkarni S; Harper A; Millis JM; Cronin DC
Liver Transpl; 2003 Nov; 9(11):1211-5. PubMed ID: 14586883
[TBL] [Abstract][Full Text] [Related]
9. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement?
Roayaie K; Feng S
Liver Transpl; 2007 Nov; 13(11 Suppl 2):S36-43. PubMed ID: 17969067
[TBL] [Abstract][Full Text] [Related]
10. Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era.
Ravaioli M; Grazi GL; Ercolani G; Cescon M; Del Gaudio M; Zanello M; Ballardini G; Varotti G; Vetrone G; Tuci F; Lauro A; Ramacciato G; Pinna AD
Transplantation; 2006 Feb; 81(4):525-30. PubMed ID: 16495798
[TBL] [Abstract][Full Text] [Related]
11. Results of the first year of the new liver allocation plan.
Freeman RB; Wiesner RH; Edwards E; Harper A; Merion R; Wolfe R;
Liver Transpl; 2004 Jan; 10(1):7-15. PubMed ID: 14755772
[TBL] [Abstract][Full Text] [Related]
12. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.
Yao FY; Bass NM; Nikolai B; Merriman R; Davern TJ; Kerlan R; Ascher NL; Roberts JP
Liver Transpl; 2003 Jul; 9(7):684-92. PubMed ID: 12827553
[TBL] [Abstract][Full Text] [Related]
13. Liver transplant recipient selection: MELD vs. clinical judgment.
Fink MA; Angus PW; Gow PJ; Berry SR; Wang BZ; Muralidharan V; Christophi C; Jones RM
Liver Transpl; 2005 Jun; 11(6):621-6. PubMed ID: 15915491
[TBL] [Abstract][Full Text] [Related]
14. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
Ioannou GN; Perkins JD; Carithers RL
Gastroenterology; 2008 May; 134(5):1342-51. PubMed ID: 18471511
[TBL] [Abstract][Full Text] [Related]
15. Model for end-stage liver disease: impact of the new deceased donor liver allocation policy in São Paulo, Brazil.
Monteiro F; Coria SA; Boni R; Pereira LA
Transplant Proc; 2009; 41(1):226-8. PubMed ID: 19249520
[TBL] [Abstract][Full Text] [Related]
16. Survival on waiting list for liver transplantation before and after introduction of the model for end-stage liver disease score.
Tenório AL; Macedo FI; Miranda LE; Fernandes JL; da Silva CM; Neto OL; Lacerda CM
Transplant Proc; 2010 Mar; 42(2):407-11. PubMed ID: 20304152
[TBL] [Abstract][Full Text] [Related]
17. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
[TBL] [Abstract][Full Text] [Related]
18. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
[TBL] [Abstract][Full Text] [Related]
19. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy.
Huo TI; Huang YH; Su CW; Lin HC; Chiang JH; Chiou YY; Huo SC; Lee PC; Lee SD
Clin Transplant; 2008; 22(4):469-75. PubMed ID: 18318736
[TBL] [Abstract][Full Text] [Related]
20. Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus.
Thuluvath PJ; Maheshwari A; Thuluvath NP; Nguyen GC; Segev DL
Liver Transpl; 2009 Jul; 15(7):754-62. PubMed ID: 19562709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
